About Aldeyra
Aldeyra is a company based in Lexington (United States) founded in 2004. Aldeyra has raised $4.79 million across 6 funding rounds from investors including Hercules Capital, Perceptive Advisors and Sphera Fund. The company has 9 employees as of December 31, 2024. Aldeyra has completed 1 acquisition, including Helio Vision. Aldeyra offers products and services including RASP Modulator Platform and ADX-2191. Aldeyra operates in a competitive market with competitors including Annexon, Nicox, Gyroscope, MeiraGTx and Alimera Sciences, among others.
- Headquarter Lexington, United States
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aldeyra Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$55.85 M (USD)-48.77as on Dec 31, 2024
-
EBITDA
-$59.87 M (USD)-40.76as on Dec 31, 2024
-
Total Equity Funding
$4.79 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Hercules Capital
& 3 more
-
Employee Count
9
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aldeyra
Aldeyra is a publicly listed company on the NASDAQ with ticker symbol ALDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aldeyra
Aldeyra offers a comprehensive portfolio of products and services, including RASP Modulator Platform and ADX-2191.
Modulates immunological systems to inhibit inflammatory cells in diseases.
Treats signs and symptoms of dry eye disease through targeted mechanisms.
People of Aldeyra
Unlock access to complete
Unlock access to complete
Funding Insights of Aldeyra
Aldeyra has successfully raised a total of $4.79M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aldeyra
Aldeyra has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, Perceptive Advisors and Sphera Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Manages hedge funds with long/short equity and real estate strategies for investors.
|
Locked | Locked | Locked |
Investor details for Aldeyra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aldeyra
Aldeyra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Helio Vision.
Investment portfolio details for Aldeyra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of small molecule based therapeutics for the treatment of eye diseases
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Aldeyra
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Aldeyra
Detailed financials for Aldeyra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aldeyra Comparisons
Peer comparison for Aldeyra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aldeyra
Aldeyra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Nicox, Gyroscope, MeiraGTx and Alimera Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized.
|
Detailed competitors of Aldeyra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aldeyra
Complete news archive for Aldeyra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldeyra
Aldeyra was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Aldeyra is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Aldeyra is a funded company, having raised a total of $4.79M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Aldeyra is 9.
Aldeyra was founded in 2004 and is based in Lexington, United States. Operations are conducted in the biotechnology sector, where drug candidates are developed to address immune-mediated diseases. The pipeline targets inflammatory cells associated with ocular and systemic conditions, including Reproxalap for dry eye disease and allergic conjunctivitis, as well as ADX-2191 for proliferative vitreoretinopathy and other programs.
Aldeyra's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Aldeyra offers RASP Modulator Platform and ADX-2191.
Yes, Aldeyra is publicly traded on NASDAQ under the ticker symbol ALDX.
Aldeyra has made 1 acquisition, including Helio Vision.
Aldeyra has 4 investors. Key investors include Hercules Capital, Perceptive Advisors, Sphera Fund, and DAFNA Capital Management.
The ticker symbol of Aldeyra is ALDX on NASDAQ.